Australia has ‘conquered’ the AstraZeneca vax clot threat: Here’s how
Haematologists were on a learning curve, but now diagnosis and treatment protocols are saving lives
Mortality from thrombosis and thrombocytopenia syndrome linked to AstraZeneca’s COVID-19 vaccine is far lower in Australia than the 25% originally touted, a leading haematologist says.
The latest figures from the TGA show 27 confirmed and six probable cases of the syndrome and include only one death.
Some 21 patients have been discharged from hospital.
Professor Huyen Tran, a Melbourne haematologist who has co-authored much of the Australian guidance on thrombosis and thrombocytopenia syndrome (TTS), said the estimated mortality rate of 25% for the syndrome was based on case outcomes before it was properly recognised and characterised.
